FDA advisory panel backs GRAIL Galleri’s benefit-risk profile

An FDA Molecular and Clinical Genetics Devices Panel voted 7–2, with one abstention, that the benefits of GRAIL’s Galleri multi-cancer early-detection blood test outweigh its risks for adults age 50 and older.

The same 10-member panel voted unanimously that Galleri is reasonably safe, but only 6–4 that there is reasonable assurance it is effective—highlighting meaningful uncertainty around clinical performance.

Key concerns included false positives, false reassurance from negative tests, and limited detection of some cancers, particularly at earlier stages. Panelists stressed that Galleri must supplement—not replace—established screening such as mammography, colonoscopy, and lung-cancer screening.

The vote is an important step toward potential FDA premarket approval, but it is advisory rather than binding. FDA retains the final decision.

GRAIL says Galleri can detect signals associated with more than 50 cancers. The test is currently prescription-only and, if approved, could become the first FDA-authorized multi-cancer blood screening test.